INTRODUCTION AND OBJECTIVES: Optimization of in vitro culture system for the expansion and the maturation of male germ cells to post meiotic stages is a valuable tool for studies exploring spermatogenesis regulation and the management of male infertility.Several studies have reported promising results of mouse spermatogonial stem cells culture in three-dimensional (3D) culture systems and a subsequent production of sperm.
METHODS: In the present study, we investigated the capacity of a three-dimensional soft agar culture system (SACS) supplemented with Knockout Serum Replacement (KSR) in colony formation and inducing human germ cells to reach post-meiotic stages. Testicular cells from testes of brain -dead donors were first cultured for three weeks in proliferation medium. The cells were subsequently cultured in the upper layer of the SACS (3D group) in a medium supplemented with KSR and hormones, and the RESULTS were compared with that of a two-dimensional (2D) culture system. RESULTS: We found that the number and diameter of colonies and the levels of expression of Scp3 and Integrin AE6 in the 3D culture group were significantly higher than in the 2D group. CONCLUSIONS: Our findings indicate that SACS can reconstruct a microenvironment capable of regulating both proliferation and differentiation of cell colonies. The last decade witnessed an increasing adoption of active surveillance (AS) as a treatment option in low-risk prostate cancer (PCa) patients. However, low-risk patients who do not fulfill the AS criteria still receive some form of local treatment, such as radical prostatectomy (RP) or radiotherapy. We tested the hypothesis that these individuals harbor a higher burden of tumor in comparison to their historic counterparts.
METHODS: We identified 164,215 clinically low-risk PCa patients (PSA less than or equal to 10 ng/ml, biopsy Gleason score less than or equal to 6, and clinical T1-T2a stage) who were treated with RP, radiotherapy, or Observation, between 2010 and 2015, within the National Cancer Database (NCDB). Patients were stratified based on treatment type, and regression analysis was used to evaluate changes in PSA values, percentage of positive cores (% PCores), and life expectancy (LE) overtime. To analyze pathological data, we focused on RP patients and used regression analysis to test changes in the rate of upgrading (pathological Gleason greater than or equal to 3þ4), upstaging (pathological greater than or equal to T3a stage), and positive surgical margins overtime, after adjusting to all available covariates. RESULTS: Median (Interquartile range [IQR]) PSA, %PCores, and LE were 5.25 (4.1-6.4) ng/mL, 25% (12.5-41.67%), and, 20.75 (15.68-24.63 ) years respectively. Among these, the %PCores changed significantly overtime among the different treatment groups. Specifically, between 2010 and 2015, mean %PCores increased from 31.33 to 32.44% in RP, 29.25 to 30.70% in radiotherapy, and decreased from 24.78 to 20.41% in AS patients (p<0.0001). On pathological data analysis, more contemporary RP patients (year 2015) showed higher rates of upgrading (54.45% vs 41.62%, p<.0001), upstaging (11.62% vs 9.03%, p<.0001), and positive surgical margins (18.08% vs 15.67%, p<.0001) than their more historic counterparts (year 2010). These findings were confirmed on multivariable analysis. CONCLUSIONS: Our findings show that contemporary low-risk PCa patients treated surgically harbor more aggressive disease than historic patients. This is an important observation that should be considered when planning surgery in these individuals, and when using pre-operative prediction models based on historic data. Several factors could have resulted in these changes, such as the increased utilization of AS, and the recommendation against PSA screening, among others.
